Pulling SEC filings + quote and writing the call…
PCVX
Vaxcyte, Inc.
Next earnings Aug 4, 2026 · consensus $-2.02 EPS
Last earnings +2.6% on 2026-05-06
$51.44
▲ +1.52%$51.44▲ +49.84%
over 1Y
L $29.67EODHDH $63.04
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.5%
1W+8.8%
1M+5.5%
3M-4.7%
YTD+10.7%
1Y+49.8%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 17 analysts
Buy
Pre-revenue vaccine developer burning $656M a year on binary Phase 3 bets — uninvestable on fundamentals.
Vaxcyte is a clinical-stage vaccine company developing next-generation pneumococcal conjugate vaccines. It has no product revenue, and the loss profile is large and widening: a net loss of -$767M in FY2025 (worse by 65.2%), an operating loss of -$924M, and diluted EPS of -$5.63. R&D spending surged 66.6% to $794M as the company funds its late-stage clinical programs, and losses have escalated every year shown (-$100M in FY2021 to -$767M in FY2025), with an accumulated deficit of -$2.15B. There is simply no earnings or revenue base on which to underwrite the stock — its value rests entirely on clinical-trial outcomes.
Sources: SEC EDGAR (CIK 0001649094, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 8:54:29 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.